SGMT

Sagimet Biosciences (SGMT) has a mean analyst price target of $26.69, suggesting 168.2% upside potential from its current $9.95 price. The stock has a Zacks Rank #2 (Buy) rating with positive earnings estimate revisions, though the article cautions that analyst price targets can be misleading and should not be the sole basis for investment decisions.

The acne vulgaris market is expected to grow steadily through 2036, driven by increasing disease prevalence affecting 85% of adolescents and young adults, and a pipeline of emerging therapies. Key players including Ascletis Pharma, Sagimet Biosciences, AOB Pharma, and Kintor Pharmaceutical are developing novel treatments like Denifanstat (ASC40), TVB-3567, B244, and GT20029 to address unmet needs in moderate-to-severe and treatment-resistant acne. The U.S. holds the largest market share, with recent approvals including clascoterone (WINLEVI) and combination therapy CABTREO expanding treatment options.